Trials / Completed
CompletedNCT00037635
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 073 | 30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally |
| DRUG | Placebo | 30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally |
Timeline
- Start date
- 2001-12-01
- Primary completion
- 2003-03-01
- Completion
- 2003-03-01
- First posted
- 2002-05-20
- Last updated
- 2013-05-08
Source: ClinicalTrials.gov record NCT00037635. Inclusion in this directory is not an endorsement.